GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks ...

Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of FGF21 that is designed to regulate key metabolic pathways to decrease liver fat, ...

Once-monthly efimosfermin demonstrated statistically significant fibrosis improvement ≥1 stage without worsening of MASH vs. placebo after 24-weeks of treatment Two-thirds of efimosfermin ...

The researchers randomly assigned 84 participants with biopsy-confirmed F2/F3 MASH to receive once-monthly injections of 300 mg efimosfermin alpha (43 patients) or placebo (41 patients) for 24 weeks.

Efimosfermin, formerly known as BOS-580, was originally developed by Novartis. Boston Pharma licensed global rights to the asset in 2020; financial terms were not disclosed. Beyond GSK’s upfront ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

Improvements in collagen formation and degradation biomarkers indicate that efimosfermin reduces fibrotic activity, consistent with histopathology findings in participants with F2 and F3 MASH after 24 ...

Together, we look forward to efimosfermin’s ongoing journey to become a best-in-class treatment for patients with SLD.” The addition of efimosfermin further strengthens GSK’s hepatology pipeline of ...